Filing Details
- Accession Number:
- 0001209191-19-049533
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-09-13 18:51:59
- Reporting Period:
- 2019-09-11
- Accepted Time:
- 2019-09-13 18:51:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1492426 | Horizon Therapeutics Public Ltd Co | HZNP | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1716059 | Irina Konstantinovsky | C/O Horizon Therapeutics Plc Connaught House, 1St Fl, 1 Burlington Rd Dublin L2 4 | Evp, Chief Human Resources Off | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2019-09-11 | 16,014 | $0.00 | 44,819 | No | 4 | A | Direct | |
Ordinary Shares | Disposition | 2019-09-11 | 7,095 | $26.71 | 37,724 | No | 4 | F | Direct | |
Ordinary Shares | Disposition | 2019-09-12 | 17,838 | $26.70 | 19,886 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Restricted Stock Units | Disposition | 2019-09-11 | 16,014 | $0.00 | 16,014 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
32,028 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on August 14, 2019.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.52 to $26.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- The restricted stock units vest in four annual installments of 16,014 shares, on each anniversary of the grant date (September 11, 2017).